Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism

NCT04209179 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT04209179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04209179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Terminated
Start date
July 23, 2020
Completion date
May 25, 2021
Enrollment
5 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism